ArticleBMC pediatrics2026
Antibiotic susceptibility profile of bacterial isolates in paediatric cancer patients: a prospective cross-sectional study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric cancer patients are highly susceptible to bloodstream infections (BSIs), which are a leading cause of morbidity and mortality in this population. However, data focusing on BSI pathogens and resistance profiles in paediatric oncology patients in Ghana are lacking. This study aimed to characterize the spectrum of bacterial pathogens and their antibiotic susceptibility patterns among paediatric cancer patients with BSIs at the national tertiary referral centre, to inform empiric therapy and infection control strategies.
methodsA prospective cross-sectional study was conducted at Korle Bu Teaching hospital from April to September 2023. Paediatric cancer patients (ages 1-18) presenting with fever on admission were consecutively sampled and enrolled, excluding those on antibiotics for BSI. Blood cultures were performed using standard microbiological techniques, and isolates were identified by conventional biochemical tests. Antimicrobial susceptibility testing was done using the modified Kirby-Bauer disk diffusion method on Mueller-Hinton agar, interpreted according to Clinical and Laboratory Standards Institute (CLSI) 2021 guidelines. Patient demographics and clinical data were collected, and infection prevalence was calculated. Associations were analysed by chi-square tests, with significance at p < 0.05.
resultsBSIs were confirmed in 22% of patients (22/100). Gram-positive organisms predominated (59.1% of isolates), chiefly Staphylococcus aureus (31.8%), coagulase-negative staphylococci (22.7%) and Streptococcus pneumoniae (4.5%). Gram-negatives (40.9%) included Klebsiella pneumoniae (18.2%), Pseudomonas aeruginosa (13.6%), and Escherichia coli (9.1%). No significant difference in BSI occurrence was observed by gender (p > 0.5). All Gram-negative isolates were susceptible to meropenem and amikacin, whereas over half of all isolates were resistant to gentamicin. For Gram-positives, cefoxitin susceptibility was 85.7% and S. aureus showed high resistance to penicillin (71.4% resistant) and gentamicin (85.7% resistant). Overall, 18.2% of isolates were multi-drug resistant (MDR) bacteria which were more common in Gram-negatives (75%) than Gram-positives (25%).
conclusionBSIs constitute a significant complication in paediatric cancer patients in this Ghanaian centre. Meropenem and amikacin were highly effective against Gram-negative bacteria, whereas substantial resistance was observed to gentamicin and ceftriaxone. There is the need to revise the empiric fever protocol at the centre to consider amikacin instead of gentamicin, The emergence of MDR organisms underscores the need for robust antibiotic stewardship and infection control measures at the oncology clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.